Popular on EntSun
- YNS ScarSaiyan Sets up For Next Release - No More (Get Back)
- Company Changes YouTube Channel Name to Steve Tristan's Best
- Skin EX Introduces Their Latest Technology for Beauty Rejuvenation
- Nutrition and Wellness Expert, Chaitra Dalton Bryant Joins the Board of the National Minority Health Association to Reduce Health Inequities
- Steve Ember, award-winning voice actor, delivers another superb performance in the noir murder and international intrigue LATE PASSENGER
- Genesis Homes is ready to take over the Cape Coral real estate market in South Florida
- G. ENTERTAINMENT proudly presents Indianapolis' Inaugural Juneteenth Celebration Weekend Kick-Off with the "What the Funk" Concert
- For Father's Day: Give Dad some Jokes he can tell that People will actually Laugh at
- SEE Company Inc. Introduces New Brand Ambassador, Ericka Dunlap at WBENC National Conference
- History-making Footwear Brand TRONUS Announces Exciting New Partnerships And Products As Company Expands This Summer
Similar on EntSun
- How Massage Therapy Near You Frees Your Body Of Pain So You Move Better, Sleep Better, Feel Better, Without Back Pain, Neck Pain, Headaches, And More!
- Mutual Aid Ambulance Service Partners with Excela Health for Paramedic Training Program
- Health Advisory: Protecting Yourself and Others from Monkeypox
- Kindle FREE June 28-29: Powerful new memoir from Santa Molina-Marshall poised to help heal abuse victims through inspiring storytelling
- Avion Medical Skin Centres to offer innovative treatment for non-melanoma skin cancer patients
- Launch of Def Leppard beauty collection creating Hysteria in the makeup industry
- iTech offers 60-days free trial on expEDIum Medical Billing® product
- Completion of funding round brings Metaphysiks one step closer to embodying the Metaverse
- CPC Scientific Announces New California Peptide API Manufacturing Facility
- Calgary-based Orthodontics Provider Opens New Location
Perth skin cancer patients undergo first treatments with OncoBeta's Rhenium-SCT as part of the EPIC-Skin study
EntSun News/10941830
PERTH, Australia - EntSun -- OncoBeta® GmbH today announced Perth's Hollywood Private Hospital in Australia is the latest medical facility to participate in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT – for the treatment of non-melanoma skin cancer [NMSC]) treating its first patients with Rhenium-SCT® as part of the international study.
The first Perth patients were treated at Hollywood Private Hospital on 3 June, and are part of 210 adults participating in the international study that will follow their progress over the next 24 months.
The EPIC-Skin study is being conducted through study centres located in Australia, Austria, Germany and the United Kingdom. The first patients to be treated globally with Rhenium-SCT® as part of the EPIC-Skin study occurred on the Gold Coast in late February, with other centres in Australian cities scheduled to participate in the study over the coming months.
Treating physician at Hollywood Private Hospital, Associate Professor Joe Cardaci, has been treating patients with Rhenium-SCT since 2018.
"Rhenium-SCT allows for a targeted and non-invasive treatment of NMSCs without damaging adjacent healthy tissue. The EPIC- Skin study offers the opportunity to further demonstrate the efficacy of this new non-invasive epidermal radioisotope therapy. With NMSCs very prevalent in Australia, it's important that as a medical community we continue to investigate new treatment options to ensure we are improving patient outcomes," said A/P Cardaci.
There are more than 7.7 million cases of NMSC each year, and incidence rates are increasing globally.1,2 Standard treatments for NMSCs are surgery-based approaches, which may have a risk of scarring or loss of function. Rhenium-SCT uses a non-invasive paste containing ß-emitting particles directly to the lesion, which target cancer cells without the need for surgery, in one single session.3-5
Dr Sam Vohra, Medical Director at OncoBeta Australia, says, "The aim of the EPIC-Skin Study is not to reverse the existing treatment options but rather to show Rhenium-SCT® is a patient friendly treatment alternative for NMSCs."
The EPIC-Skin study will measure Patient Reported Outcomes such as quality of life, treatment comfort and cosmetic outcomes, as well as further evaluating the efficacy of Rhenium-SCT for the treatment of NMSC. To provide a simple and streamlined way to record their experiences, patients in the study will utilise the Clinical Study app.
More on EntSun News
Shannon D. Brown III, CEO and Managing Director at OncoBeta, says, "NMSC is a significant health concern in Australia and around the world. This study will offer new insights into the treatment of NMSC and the role of Rhenium-SCT® in the suite of treatments available to patients. The EPIC-Skin Study will be critical in assisting us in improving patient outcomes for those suffering with NMSCs."
Clinicians who are interested in enrolling patients in the study can contact OncoBeta directly at www.oncobeta.com/contact.
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.2 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.6
The Rhenium-SCT® is a painless*, single session†, non-invasive therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.3-5 The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalised therapy that is only applied to the area needed to treat without affecting the healthy tissue. The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT in one single session.†5 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.5
About OncoBeta®
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.
More on EntSun News
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: www.linkedin.com/company/oncobeta-gmbh/
Facebook: www.facebook.com/oncobeta/
Instagram: www.instagram.com/oncobeta_gmbh/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain3,4
†Complete tumour regression in 98.5% of lesions treated, with 89% after a single application5
References
The first Perth patients were treated at Hollywood Private Hospital on 3 June, and are part of 210 adults participating in the international study that will follow their progress over the next 24 months.
The EPIC-Skin study is being conducted through study centres located in Australia, Austria, Germany and the United Kingdom. The first patients to be treated globally with Rhenium-SCT® as part of the EPIC-Skin study occurred on the Gold Coast in late February, with other centres in Australian cities scheduled to participate in the study over the coming months.
Treating physician at Hollywood Private Hospital, Associate Professor Joe Cardaci, has been treating patients with Rhenium-SCT since 2018.
"Rhenium-SCT allows for a targeted and non-invasive treatment of NMSCs without damaging adjacent healthy tissue. The EPIC- Skin study offers the opportunity to further demonstrate the efficacy of this new non-invasive epidermal radioisotope therapy. With NMSCs very prevalent in Australia, it's important that as a medical community we continue to investigate new treatment options to ensure we are improving patient outcomes," said A/P Cardaci.
There are more than 7.7 million cases of NMSC each year, and incidence rates are increasing globally.1,2 Standard treatments for NMSCs are surgery-based approaches, which may have a risk of scarring or loss of function. Rhenium-SCT uses a non-invasive paste containing ß-emitting particles directly to the lesion, which target cancer cells without the need for surgery, in one single session.3-5
Dr Sam Vohra, Medical Director at OncoBeta Australia, says, "The aim of the EPIC-Skin Study is not to reverse the existing treatment options but rather to show Rhenium-SCT® is a patient friendly treatment alternative for NMSCs."
The EPIC-Skin study will measure Patient Reported Outcomes such as quality of life, treatment comfort and cosmetic outcomes, as well as further evaluating the efficacy of Rhenium-SCT for the treatment of NMSC. To provide a simple and streamlined way to record their experiences, patients in the study will utilise the Clinical Study app.
More on EntSun News
- Mutual Aid Ambulance Service Partners with Excela Health for Paramedic Training Program
- Carmen : A short film thriller
- U.S. Army Field Band Soldiers' Chorus Perform Free Concert at Weinberg Center
- In2Scuba Diving Co. of Maui introduces its exclusive beginner scuba diving lessons
- Entertainment Company Zen Arts Made Sure Pure Accelerate® techfest22 Was Utterly Unforgettable With Breathtaking Performances
Shannon D. Brown III, CEO and Managing Director at OncoBeta, says, "NMSC is a significant health concern in Australia and around the world. This study will offer new insights into the treatment of NMSC and the role of Rhenium-SCT® in the suite of treatments available to patients. The EPIC-Skin Study will be critical in assisting us in improving patient outcomes for those suffering with NMSCs."
Clinicians who are interested in enrolling patients in the study can contact OncoBeta directly at www.oncobeta.com/contact.
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer in humans.2 The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.6
The Rhenium-SCT® is a painless*, single session†, non-invasive therapy that provides aesthetic results, even in cases otherwise considered difficult to treat.3-5 The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalised therapy that is only applied to the area needed to treat without affecting the healthy tissue. The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the patient's skin and the application is safe and simple for the applying physician. Most cases of NMSCs (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT in one single session.†5 Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.5
About OncoBeta®
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.
More on EntSun News
- Always Ontime: Chaos City - Super Hero Graphic Novel with Neal Adams Cover Launches from Panopolis Metaverse
- New Hampshire Becomes the 15th State to Require Personal Finance as a Core Academic Subject
- Virtual Workplace Platform Developer REACH Expands Executive Team, Positioning the Company to Drive International Growth
- A New Age of Phantom Breaker Dawns
- Health Advisory: Protecting Yourself and Others from Monkeypox
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: www.linkedin.com/company/oncobeta-gmbh/
Facebook: www.facebook.com/oncobeta/
Instagram: www.instagram.com/oncobeta_gmbh/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
*No reported pain3,4
†Complete tumour regression in 98.5% of lesions treated, with 89% after a single application5
References
- Global Burden of Disease Cancer Collaboration, et al. JAMA Oncol. 2019;5(12):1749-1768.
- Ciążyńska M, et al. Sci Rep. 2021;11(1):4337.
- Cipriani C, et al. J Dermatolog Treat. 2020; Jul 22:1-7.
- Sedda AF, et al. Clin Exp Dermatol. 2008;33(6):745-749.
- Cipriani C, Sedda AF. Epidermal Radionuclide Therapy - Dermatological High-Dose-Rate. Brachytherapy for the Treatment of Basal and Squamous Cell Carcinoma. In: Therapeutic Nuclear Medicine, editor Baum RP; New York: Springer, 2014.
- Cancer.net. Skin Cancer (Non-Melanoma): Risk Factors and Prevention. October 2020. https://www.cancer.net/cancer-types/skin-cancer-non-melanoma/risk-factors-and-prevention (accessed March 2022).
Source: OncoBeta GmbH
Filed Under: Beauty
0 Comments
Latest on EntSun News
- red white and blue Viernes Tropicales Latin Night @ Sanctuary Night Club July 1st
- 3hr Salsa Class Atlanta - Beginner/Beyond Basics July 2nd
- Ismail Sirdah' Guide To Landing Event Sponsorships
- Children's Shoe Brand joins Soles4Souls in Ukrainian Refugee Relief Efforts
- The Data Economics Company announces partnership with Incradia to release the ReVerse franchise on Lydion-based Game Development Platform
- iTech offers 60-days free trial on expEDIum Medical Billing® product
- Completion of funding round brings Metaphysiks one step closer to embodying the Metaverse
- On Anniversary of Surfside Tragedy, New Book Coaches Residents to Identify Warning Signs
- Marc Yaffee From Dry Bar Comedy Comes to McMinnville Saturday June 2
- What's Inside That Sexy Mind of Yours? at NCRT Variety Nights
- CHASM unveils highly-respected CEO John Kawola as its first independent board member
- IOTech announces a major new release of Edge XRT, its software platform for time-critical OT systems
- Holidays365 Film Festival Summer Edition Starts Saturday
- Connect Fibre Partners With Linksys and Axiros
- Bacchus Wine & Spirits Jumps To Elite 'Top 20' Position In Beverage Dynamics Top 100 Retailers for 2022
- Comedian Marc Yaffee Returns to Craft Kitchen & Brewery Friday July 1
- Soundtrack for the "All I Need Is Your Signature" Released on the Ulterground Records
- CPC Scientific Announces New California Peptide API Manufacturing Facility
- PermaTherm 2022 Family Fun Day
- New development in Ramsey called Williams Woods!